SynthesisMedicine2019
The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis.
Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Toward Precision Imaging in Lung NET: A Clinically Oriented Framework Integrating Dual Tracer PET and Radiomics.Cancers · 2026Review
- National analysis of the incidence and prognostic importance of nodal metastases in atypical lung carcinoid tumors.JTCVS open · 2026Article
- Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5-HIAA: A Case Report.Case reports in endocrinology · 2026Article
- Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- A Challenging Case of Ectopic Adrenocorticotropin Hormone Syndrome with Bronchial Carcinoid and Literature ReviewJournal of clinical research in pediatric endocrinology · 2025Review
- Review
- Neuroendocrine Neoplasms of the Lungs, Thyroid, and Thymus.Biomedicines · 2025Review
- Recognition and Management of Ectopic ACTH Secreting Tumors.Journal of the Endocrine Society · 2025Article
- Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.European journal of nuclear medicine and molecular imaging · 2024Review
- Non-metastatic causes of multiple pulmonary nodules.Insights into imaging · 2024Article
- Positron emission tomography in the diagnosis and management of primary pediatric lung tumors.Pediatric radiology · 2024Review
- A Systematic Review on Combined [Journal of clinical medicine · 2023Review
- Site-specific performance ofFrontiers in oncology · 2023Article
- Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.European journal of nuclear medicine and molecular imaging · 2022Observational
- Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.Cancers · 2022Review
- Clinicopathological, Oncogenic, andContrast media & molecular imaging · 2022Article
- PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.Cancers · 2021Review
- Contribution ofMolecular imaging and radionuclide therapy · 2021Article
- Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary carcinoids (PC) are histologically classified into typical carcinoid (TC) and atypical carcinoid (AC). The diagnosis of pulmonary carcinoid and possibly the differentiation between TC and AC could make a significant effect on the treatment planning as well as prognosis. Several studies have explored the utility of Ga-DOTA-Peptide (Ga-labelled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-peptide) and F-flurodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in the evaluation of primary pulmonary carcinoids. Therefore, we performed a meta-analysis to evaluate the diagnostic accuracy and prediction efficiency of histological subtypes of these two imaging modalities in primary PC.
methodsRelevant studies were identified by searching PubMed, Web of Science, and EMBASE published from 2006 to 2016. Two authors extracted characteristics of patients and their lesions using predefined criteria.
resultsFourteen studies comprising 352 patients were included in this meta-analysis. The pooled sensitivity of Ga-DOTA-Peptide and F-FDG PET/CT in detecting pulmonary carcinoid were 90.0% (95% CI = 82.0-95.0%; P = .07; I = 49.6%) and 71.0% (95% CI = 66.0-76.0%; P < .001; I = 59.3%), respectively. An SUVmax ratio between Ga-DOTA-Peptide and F-FDG higher than the cutoff value of 4.28 was predictive of TC with 89.3% sensitivity and 100% specificity (AUC, 96.4%; 95% CI, 91.1-100%). The ratio of tumor uptake to atelectatic lung uptake was significantly higher for Ga-DOTA-peptide (2.5-91, mean 30.5 ± 28.1) than for F-FDG (0.3-10.3, mean 2.1 ± 2.3) (P < .001).
conclusionsBoth Ga-DOTA-peptide and F-FDG are highly sensitive in detecting pulmonary carcinoid, while Ga-DOTA-peptide is more sensitive than F-FDG (90.0% vs 71.0%). The SUVmax ratio was an accurate predictor of the histopathologic variety of the carcinoid tumor, and Ga-DOTA-peptide was better than F-FDG in cases with atelectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.